Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high…
Overview of attention for article published in Leukemia & Lymphoma, March 2015
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (77th percentile)
-
High Attention Score compared to outputs of the same age and source (89th percentile)
Readers on
- mendeley
- 50 Mendeley